Cato Research

Cato Research, Ltd. is a full service contract research and development organization (also known as clinical research organization or "CRO"), which serves the pharmaceutical, biotechnology and healthcare industries. Cato Research serves these industries by aiding companies in navigating the complex regulatory approval process in order to bring new drugs, biologics and medical devices to market. This page is significant because Cato Research was the first CRO to establish a venture arm which exchanges development services for equity in early stage pharmaceutical companies (for more information, see section 4 Cato BioVentures)

History

Dr. Allen Cato and Lynda Sutton founded Cato Research in 1988 as a contract research and development organization to help pharmaceutical and biotechnology companies design and execute successful development strategies. From the beginning, Cato Research has been recognized for their knowledge of science and technology, as well as their ability to guide creative new products through the regulatory process.

Worldwide Locations

Cato Research has taken a controlled-growth approach, expanding its operations selectively across North America and the world. Headquartered near Research Triangle Park in North Carolina, worldwide offices include:
*United States:
**Boston, MA
**San Diego, CA
**San Francisco, CA
**Washington, DC
*Worldwide Locations:
**Montreal, Quebec
**Cologne, Germany
**Frankfurt, Germany
**Graz, Austria
**Tel Aviv, Israel
**Johannesburg, South Africa
**Riga, Latvia
*Regional Staff or Strategic Alliances:
**Zagreb, Croatia
**Bucharest, Romania
**Hyderabad, India
**Basel Switzerland

Services

Cato Research offers a wide range of services and strategic consulting in the following areas:
*Non-Clinical
*Clinical Trials
*Pharmacovigilance
*Regulatory
*Pharmaceutical Product Development
*Compliance
*Integrated Drug Development
*Project Management Office
*Investigator Registry

Cato BioVentures

Cato BioVentures is a separate arm of Cato Research which works with emerging, early stage pharmaceutical and biotechnology companies to assist them with early development objectives. Because these early stage companies are often short on both human and monetary capital, Cato BioVentures provides development services in exchange for equity. Companies must undergo a thorough due diligence process and must have a promising drug candidate, particularly one that meets an unmet need, in order to be considered for Cato BioVentures support. Although several CROs in the industry now incorporate this partnership model into their business, Cato Research was an industry leader in this area and was the first to launch such a component.

Main Menu

See Also

Main Menu